

**Supplemental Table S4.** Percentage of patients achieving Psoriasis Area and Severity Index (PASI) 50, PASI 75, and PASI 90 at weeks 12, 24, 36, and 48 during secukinumab treatment.

	PASI 50 (%)				PASI 75 (%)				PASI 90 (%)			
	Without bio-failure	With bio-failure	P value	Total	Without bio-failure	With bio-failure	P value	Total	Without bio-failu re	With bio-failure	P value	Total
Week 4	40/53 (75.5%)	42/65 (64.6%)	0.20	82/118 (69.5%)	14/53 (28.7%)	26/65 (38.5%)	0.25	40/118 (33.9%)	8/53 (15.1%)	10/65 (15.4%)	0.97	18/118 (15.3%)
week 12	50/50 (100%)	57/65 (87.7%)	0.01*	107/115 (93.0%)	39/50 (78.0%)	35/65 (53.8%)	0.007**	74/115 (64.3%)	15/50 (30.0%)	17/65 (26.2%)	0.65	32/115 (27.8%)
Week 24	43/43 (100%)	50/57 (87.7%)	0.02*	93/100 (93%)	34/43 (79.1%)	29/57 (50.9%)	<0.004**	63/100 (63%)	14/43 (32.6%)	18/57 (31.6%)	0.92	32/100 (32.0%)
Week 36	26/28 (92.9%)	42/50 (84.0%)	0.26	68/78 (87.2%)	20/28 (71.4%)	27/50 (54.0%)	0.13	47/78 (60.3%)	16/28 (57.1%)	11/50 (22.0%)	0.002**	27/78 (34.6%)
Week 48	18/18 (100%)	31/36 (86.1%)	0.10	49/54 (90.7%)	13/18 (72.2%)	16/36 (44.4%)	0.054	29/54 (53.7%)	8/18 (44.4%)	7/36 (19.4%)	0.053	15/54 (27.8%)

\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 for comparison between patients with and without prior biologic failure.